共 346 条
[1]
Thuss-Patience PC(2011)Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Eur J Cancer 47 2306-2314
[2]
Kretzschmar A(2014)Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial Lancet Oncol 15 78-86
[3]
Bichev D(2012)Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone J Clin Oncol 30 1513-1518
[4]
Deist T(2013)Gastric cancer-molecular and clinical dimensions Nat Rev Clin Oncol 10 643-655
[5]
Hinke A(2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-697
[6]
Breithaupt K(2010)The PI3 K pathway as drug target in human cancer J Clin Oncol 28 1075-1083
[7]
Dogan Y(2009)Targeting PI3 K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer 9 550-562
[8]
Gebauer B(2014)The role of PI3 K/Akt/mTOR signaling in gastric carcinoma Cancers 6 1441-1463
[9]
Schumacher G(2009)Relation between outcomes and localisation of p-mTOR expression in gastric cancer Br J Cancer 100 782-788
[10]
Reichardt P(2009)Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer Clin Cancer Res 15 1821-1829